secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001104659-26-034523
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharma Q4 net loss $124.3M on $105.8M non-cash fair value loss; going concern noted
--------------------------------------------------------------------------------

- Q4 2025 grant revenue $1.1M vs $1.2M YoY; R&D expenses $6.1M vs $8.5M YoY.
- Net loss $124.3M ($3.42/sh) vs net income $2.6M ($0.07/sh) in Q4 2024; includes $105.8M non-cash fair value loss on convertible loan.
- Recognized $5.4M impairment expense on vacated Marina del Rey office lease.
- Cash & equivalents $14.1M as of Dec 31 2025; amended debt agreements extending maturities to June 2027.
- Audited 2025 financials include going concern qualification; ~36.6M shares outstanding as of Mar 18 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465926034523/0001104659-26-034523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465926034523/armp-20260325x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-034523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer